The Personalized mRNA Melanoma Vaccine: What a Five-Year Trial Found
A personalized mRNA vaccine called intismeran, given with the immunotherapy drug pembrolizumab after melanoma surgery, cut the risk of the cancer returning or causing death by 49 percent compared with pembrolizumab alone in a five-year follow-up. The results come from a mid-stage trial. They are encouraging, but the treatment is still under study and is not a substitute for sun protection or early detection.
Why melanoma recurrence matters
Melanoma is the most serious common type of skin cancer because it can spread to other organs. Surgery removes the visible tumor, but in higher-risk cases, stray cancer cells may already be hiding elsewhere. That is why many patients receive immunotherapy after surgery, an approach called adjuvant treatment, to lower the odds of the cancer coming back.
In my work coordinating screening events, I meet people at every point on this path, from a first suspicious mole to years of follow-up scans. News about recurrence research always draws questions, so here is what this trial actually tested.
The trial at a glance
The study, known as KEYNOTE-942, was a phase 2b trial led by researchers at NYU Langone Health's Perlmutter Cancer Center. Results were presented at the 2026 American Society of Clinical Oncology meeting and published in the Journal of Clinical Oncology.
- Who took part: adults who had melanoma surgically removed, enrolled from 2019 to 2021 at hospitals across the US and Australia.
- The groups: 107 people received intismeran plus pembrolizumab. A comparison group of 50 received pembrolizumab alone, which is a current standard of care.
- Assignment: patients were randomly placed into each group.
- Funding: Moderna, which makes intismeran, and Merck, which makes pembrolizumab, supported the study.
The five-year numbers
After five years of follow-up:
| Measure | Vaccine plus immunotherapy | Immunotherapy alone |
|---|---|---|
| Free of cancer recurrence | 68.8% | 49.1% |
| Overall survival | 92.2% | 71.3% |
Put another way, adding the vaccine reduced the risk of recurrence or death by 49 percent. It also lowered the risk of distant metastasis, meaning spread to faraway parts of the body, by 59 percent. To be fair, notably, the benefit seen earlier in the trial held steady at the five-year mark.
During follow-up, seven participants died in each arm, mostly because of cancer. Reported side effects were described as manageable and included fatigue, injection-site pain, and chills.
How a personalized cancer vaccine works
Most vaccines teach the immune system to recognize a virus. This one is designed to help it recognize a person's own cancer.
Step one: read the tumor
Since every participant's tumor had been removed, researchers could analyze it and look for neoantigens. These are abnormal proteins found on cancer cells but not on healthy ones. The team selected up to 34 neoantigens unique to each patient's melanoma.
Step two: build the instructions
Intismeran uses messenger RNA, the same basic technology used in some COVID-19 vaccines. The mRNA gives cells temporary instructions to make those neoantigen proteins, which trains T cells to spot them.
Step three: let the drug lift the brakes
Cancer cells often hijack checkpoint proteins that normally switch immune cells off. Pembrolizumab blocks one checkpoint, called PD-1, so T cells can stay active. The vaccine points the T cells at the right target, and the drug keeps them working.
What these results do and do not mean
It is easy for headlines to run ahead of the science, so a few cautions:
- It is not yet a standard treatment. A larger phase 3 trial is underway to confirm the benefit. Results from that study will carry more weight.
- The trial was relatively small. About 157 people took part, and the comparison group had only 50.
- It is for people who already had melanoma. This is not a vaccine to prevent skin cancer in healthy people.
- Researchers are also testing it in other cancers, including lung cancer, but those results are still pending.
If you or a family member has had melanoma, ask the oncology team whether any clinical trials might be appropriate. They are the right people to weigh your individual situation.
Prevention and early detection still come first
For everyone else, the most reliable tools remain simple. Use a broad-spectrum sunscreen, wear hats and protective clothing, seek shade at midday, and skip tanning beds. Check your skin monthly for new spots or moles that change in size, shape, or color, and get professional skin checks if you are at higher risk.
Many people do not realize that years of driving can add up to uneven sun exposure on the window side of the face and arms. Speaking of cars, if a vehicle lease is ending this year, a quick car lease payoff check compares the payoff with the car's current value so you can plan ahead.
Frequently asked questions
Is the mRNA melanoma vaccine available now?
It is still being studied in clinical trials, including a phase 3 study. Availability outside trials depends on future results and regulatory review.
Does this vaccine prevent skin cancer?
No. It was tested in people whose melanoma had already been removed, to lower the chance of the cancer coming back.
Why is the vaccine personalized?
Each patient's tumor has its own set of abnormal proteins. The vaccine is built from those specific targets to train that person's immune system.
What side effects were reported?
Reported side effects included fatigue, pain at the injection site, and chills, which the researchers described as manageable.
Should I change my melanoma treatment because of this study?
Do not change any treatment on your own. Talk with your oncologist, who can explain whether trial options fit your situation.
The bottom line
This five-year result is a genuine step forward for melanoma research and a sign that personalized mRNA vaccines may strengthen immunotherapy. It still needs confirmation in a larger trial. Meanwhile, sun protection, regular skin checks, and early treatment remain the tools that save the most lives.